Showing 5291-5300 of 9152 results for "".
- Evolving Approaches to Treating Melasma Highlighted at AADhttps://practicaldermatology.com/news/Evolving-Approaches-Treating-Melasma-Highlighted-AAD/2471546/Use of imaging and aggressive treatment are critical in the medical management of melasma in 2025, Mukta Bhardwaj Sachdev,MD, IFAAD, said at the 2025 American Academy of Dermatology (AAD) Annuel Meeting in Orlando, Florida. “You need to use imaging systems, monitor your patients, [use] top
- Get In First: A Derm's Case for Early Psoriasis Treatmenthttps://practicaldermatology.com/news/from-aad-2025-a-case-for-early-psoriasis-treatment/2471544/Addressing psoriasis early in its course may lead to prolonged remission and better outcomes, and dermatologists should take note, according to a presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
- ICONIC-LEAD: Icotrokinra Clears Almost Half of Psoriasis Patients in Phase 3 Trialhttps://practicaldermatology.com/news/iconic-lead-icotrokinra-clears-almost-half-of-psoriasis-patients-in-phase-3-trial/2471543/Nearly half of patients with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin at week 24, according to new data presented at the 2025 America Academy of Dermatology Annual Meeting. The
- Study: 60% Lesion Clearance in Actinic Keratosis Patients Using Topical Bimiralisib Gelhttps://practicaldermatology.com/news/study-60-lesion-clearance-in-actinic-keratosis-patients-using-topical-bimiralisib-gel/2471542/Newly presented interim results from a phase 2 clinical trial evaluating bimiralisib topical gel (2%) saw more than half of patients with actinic keratosis achieving complete or partial lesion clearance. Bimiralisib, a pan-PI3
- Almirall Presents Early-Stage Pipeline Progress for Tirbanibulinhttps://practicaldermatology.com/news/Almirall-Presents-Early-Stage-Pipeline-Progress-Tirbanibulin/2471540/Almirall, S.A. presented five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, including new data on tirbanibulin, a topical treatment for actinic keratosis (AK), and progress of its early-stage asset LAD191, a high-affinity monoclonal antib
- AAD Posters Highlight Positive Data for Roflumilasthttps://practicaldermatology.com/news/AAD-Posters-Highlight-Positive-Data-Roflumilast/2471539/Arcutis Biotherapeutics, Inc., announced new data from two posters shared at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. The first poster presentation details the positive efficacy, patient-reported outcomes, and tolerability for the use of once-daily
- IEC Session Highlights AA/AD Connectionhttps://practicaldermatology.com/news/IEC-Session-Highlights-AA-AD-Connection/2471516/The International Eczema Council (IEC) meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, was a crossover event. The IEC partnered with both the National Eczema Association (NEA) and National Alopecia Areata Foundation (NAAF) to present
- Analysis: Biosimilars Show Comparable Effectiveness to Humira in Psoriasishttps://practicaldermatology.com/news/analysis-biosimilars-show-comparable-effectiveness-to-humira-in-psoriasis/2471496/Adalimumab biosimilars Amjevita and Imraldi showed similar effectiveness to Humira for the treatment of psoriasis in both new users and patients switching from Humira, according to an analysis of the British Association of Dermatologists Biologics and Immunomodulato
- Closing Gaps: Takeda Enhances Diversity in Psoriasis Trialshttps://practicaldermatology.com/news/closing-gaps-takeda-enhances-diversity-in-psoriasis-trials/2471442/Takeda’s phase 3 psoriasis (PsO) clinical trials in the United States achieved success in enhancing racial and ethnic diversity among participants, according to new data from the manufacturer. Psoriasis affects over 7.5 millio
- TSC Reduces Tretinoin-Induced Skin Irritation: Pilot Studyhttps://practicaldermatology.com/news/tsc-reduces-tretinoin-induced-skin-irritation-pilot-study/2471409/A recent pilot study has shown that tetramethylhexadecenyl succinoyl cysteine (TSC) significantly reduces erythema and dryness caused by tretinoin application. These findings may offer a novel approach to minimizing the common adverse effects of tretinoin, potential